Skip to main content
OpenTrials
Completed

NCT Number: NCT05287100

To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.

Children with cirrhosis awaiting transplantation are more proned to develop various complications. The pathogenesis of cirrhotic complications (ascites, hyponatremia, acute kidney injury) includes release of vasodilatory molecules like nitric oxide, damage associated molecular pathogens (DAMPs) and pattern associated molecular pathogens (PAMPs) secondary to bacterial translocation, which causes splanchnic bed vasodilation resulting in activation of renin-angiotensin and aldosterone axis(RAAS) causing sodium and water retention and renal vasoconstriction [1].

The development of complications in these children may result in death or may preclude them from reaching upto liver transplantation [2].

Midodrine is an α1 adrenergic receptor agonist, which increases vascular tone causing rise in the blood pressure, thereby improving renal perfusion and causes RAAS deactivation. The effects of midodrine is documented in reduction of refractory ascites, hepatorenal syndrome and hyponatremia[2-4].

One group will receive only standard medical therapy and other group will receive midodrine and standard medical therapy for 6 months. Mean arterial pressure will be monitored at every OPD visit. At the end of 12 weeks, and 24 weeks, plasma renin activity, incidence of complications related to cirrhosis like new onset ascites, increase in grade of ascites, hyponatremia, acute kidney injury and spontaneous bacterial peritonitis will be assessed. Also the transplant free survival and need for albumin transfusion will be compared between the two groups.

In case of liver transplantation or death before 6 months, midodrine will be stopped

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cirrhosis, Liver Digestive System Diseases Fibrosis Liver Cirrhosis Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

10 day–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institute of liver and biliary sciences

New Delhi, 110070, India

About this study

Aim: To determine the efficacy of midodrine in preventing development of complications in children with cirrhosis awaiting liver transplantation

Primary Objective:

  • To compare incidence of complications (Acute kidney injury, New onset ascites or increase in grade of ascites, Spontaneous bacterial peritonitis, Hyponatremia, Hepatic encephalopathy) of cirrhosis in patients receiving midodrine (at a dose of 0.25 - 0.5mg/kg/day) and standard medical therapy versus standard medical therapy alone for 6 months

Secondary Objectives:

  • Frequency of development of new onset ascites or increase in grade of ascites by 6 months
  • Change in serum sodium from baseline to 6 months
  • Change in Mean arterial pressure (MAP) at 1 week and then 2 weekly till the end of the study
  • Plasma renin activity at baseline, at 12 weeks and 24 weeks
  • Frequency of development of SBP over 6 months
  • Change in eGFR from baseline to 6 months
  • Frequency of developing AKI by 6 months
  • Frequency of development of Hepatic encephalopathy by 6 months
  • Proportion of patients developing hypertension at 6 months
  • Frequency of development of drug related adverse effects by 6 months
  • Requirement of albumin infusion in 2 groups
  • Transplant free survival

Methodology:

  • Study population :Children and Adolescents of age group upto 18 years with cirrhosis and PELD/ MELDNa score more than 14, on waitlist for liver transplantation following up in the Pediatric Hepatology Department
  • Study design: Open label RCT (computer based randomization - block randomization with block size of 4)
  • Study period: 6 months weeks for each patient; The study will be conducted between January 2022 and July 2023
  • Sample size:
  • Pilot study - 10 patients in each group

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children and Adolescents of age group upto 18 years with cirrhosis and PELD/ MELDNa score more than 14, on waitlist for liver transplantation following up in the Pediatric Hepatology Department, ILBS will be prospectively included in this study after informed consent

Exclusion criteria

Presence of Portal vein thrombosis Renal or cardiovascular disease or arterial hypertension Presence of HCC

Treatment and study plan

Midodrine Oral Tablet

Drug

Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued

Standard Medical Treatment

Other

Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is < 2.8g/dl SBP - Day 1 and Day 3

For Ascites :

Restriction of sodium to < 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites

For Spontaneous Bacterial Peritonitis :

IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3

Primary outcomes

  1. Complications between the two groups

    Time frame: 6 months

    • To compare incidence of complications (Acute kidney injury, New onset ascites or increase in grade of ascites, Spontaneous bacterial peritonitis, Hyponatremia, Hepatic encephalopathy) of cirrhosis in patients receiving midodrine (at a dose of 0.25 - 0.5mg/kg/day) and standard medical therapy versus standard medical therapy alone for 6 months

Secondary outcomes

  1. • Frequency of development of new onset ascites or increase in grade of ascites by 6 months

    Time frame: 6 months

  2. Change in serum sodium from baseline to 6 months

    Time frame: 6 months

  3. Change in Mean arterial pressure (MAP) at 1 week and then 2 weekly till the end of the study

    Time frame: 6 months

  4. Plasma renin activity at baseline, at 12 weeks and 24 weeks

    Time frame: 6 months

  5. Frequency of development of SBP over 6 months

    Time frame: 6 months

  6. Change in eGFR from baseline to 6 months

    Time frame: 6 months

  7. Frequency of developing AKI by 6 months

    Time frame: 6 months

  8. Frequency of development of Hepatic encephalopathy by 6 months

    Time frame: 6 months

  9. Proportion of patients developing hypertension at 6 months

    Time frame: 6 months

  10. Frequency of development of drug related adverse effects by 6 months

    Time frame: 6 months

  11. Requirement of albumin infusion in 2 groups

    Time frame: 6 months

  12. Transplant free survival

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Institute of Liver and Biliary Sciences, India

Other

Registry information

Official study title

To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 18, 2022
Registry last updated
Oct 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.